582 related articles for article (PubMed ID: 9598885)
1. Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology outpatient clinic.
Vlachoyiannopoulos PG; Tzavara V; Dafni U; Spanos E; Moutsopoulos HM
J Rheumatol; 1998 May; 25(5):886-91. PubMed ID: 9598885
[TBL] [Abstract][Full Text] [Related]
2. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus.
Faria AC; Barcellos KS; Andrade LE
J Rheumatol; 2005 Jul; 32(7):1267-72. PubMed ID: 15996063
[TBL] [Abstract][Full Text] [Related]
4. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
[TBL] [Abstract][Full Text] [Related]
5. Outcome of positive antinuclear antibodies in individuals without connective tissue disease.
Myckatyn SO; Russell AS
J Rheumatol; 2003 Apr; 30(4):736-9. PubMed ID: 12672192
[TBL] [Abstract][Full Text] [Related]
6. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of antinuclear antibody tests in children.
McGhee JL; Kickingbird LM; Jarvis JN
BMC Pediatr; 2004 Jul; 4():13. PubMed ID: 15245579
[TBL] [Abstract][Full Text] [Related]
8. Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians.
Suarez-Almazor ME; Gonzalez-Lopez L; Gamez-Nava JI; Belseck E; Kendall CJ; Davis P
J Rheumatol; 1998 Oct; 25(10):1980-5. PubMed ID: 9779854
[TBL] [Abstract][Full Text] [Related]
9. The pathogenic 16/6 idiotype in patients with silica associated systemic lupus erythematosus (SLE) and uranium miners with increased risk for development of SLE.
Conrad K; Levy Y; Blank M; Mehlhorn J; Frank KH; Roch B; Shoenfeld Y
J Rheumatol; 1998 Apr; 25(4):660-6. PubMed ID: 9558166
[TBL] [Abstract][Full Text] [Related]
10. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases.
Salonen EM; Miettinen A; Walle TK; Koskenmies S; Kere J; Julkunen H
Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381
[TBL] [Abstract][Full Text] [Related]
11. Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases.
Tektonidou MG; Anapliotou M; Vlachoyiannopoulos P; Moutsopoulos HM
Ann Rheum Dis; 2004 Sep; 63(9):1159-61. PubMed ID: 15308528
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease.
Reichlin M; Broyles TF; Hubscher O; James J; Lehman TA; Palermo R; Stafford HA; Taylor-Albert E; Wolfson-Reichlin M
Arthritis Rheum; 1999 Jan; 42(1):69-75. PubMed ID: 9920016
[TBL] [Abstract][Full Text] [Related]
13. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus.
Hoffman IE; Peene I; Meheus L; Huizinga TW; Cebecauer L; Isenberg D; De Bosschere K; Hulstaert F; Veys EM; De Keyser F
Ann Rheum Dis; 2004 Sep; 63(9):1155-8. PubMed ID: 15308527
[TBL] [Abstract][Full Text] [Related]
14. [Anti-SSA/Ro and anti-SSB/La antibodies. What's new?].
Meyer O
Ann Med Interne (Paris); 2002 Dec; 153(8):520-9. PubMed ID: 12610426
[TBL] [Abstract][Full Text] [Related]
15. [Undifferentiated connective tissue disease: clinical and serological profile of 578 patients followed for five years: disease course, prognosis and therapy].
Bodolay E; Szegedi G
Orv Hetil; 2002 Feb; 143(5):229-33. PubMed ID: 11875835
[TBL] [Abstract][Full Text] [Related]
16. [The clinical immunology laboratory in diagnosis and monitoring of systemic lupus erythematosus and connective tissue diseases].
Sinico RA; Radice A
G Ital Nefrol; 2005; 22 Suppl 33():S21-6. PubMed ID: 16419001
[TBL] [Abstract][Full Text] [Related]
17. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus.
Amoura Z; Koutouzov S; Chabre H; Cacoub P; Amoura I; Musset L; Bach JF; Piette JC
Arthritis Rheum; 2000 Jan; 43(1):76-84. PubMed ID: 10643702
[TBL] [Abstract][Full Text] [Related]
18. [The autoantibody profile and disease activity in patients with systemic lupus erythematosus].
Horák P; Hermanová Z; Faltýnek L; Pospísil Z; Scudla V
Vnitr Lek; 1997 Oct; 43(10):639-44. PubMed ID: 9601876
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological evaluation of in vivo epidermal nuclear fluorescence.
Sousa JX; Miyamoto D; Zimbres JM; Costa DV; Aoki V
Clin Exp Dermatol; 2009 Apr; 34(3):314-8. PubMed ID: 19040522
[TBL] [Abstract][Full Text] [Related]
20. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus.
Sjöwall C; Sturm M; Dahle C; Bengtsson AA; Jönsen A; Sturfelt G; Skogh T
J Rheumatol; 2008 Oct; 35(10):1994-2000. PubMed ID: 18785312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
